NEW YORK (GenomeWeb News) – Paul MacLeman, CEO of Australian firm Genetic Technologies, and other members of the firm's board and executive team resigned Tuesday following the firm's annual general meeting.

The resignations came after Chairman Mel Bridges and Director Huw Jones were not re-elected to the firm's board. Those two will leave the board along with Director Greg Brown, who resigned following the results of the voting even though he was re-elected. David Sparling, VP of legal and corporate development for the firm, also tendered his resignation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: ancestry and admixture in Brazilians, characterization of novel double-stranded RNA mycovirus, and more.

Researchers report that what scents someone picks up can reflect their complement of immune genes.

The New York Times examines ethics and China's push to lead biomedical research.

At her blog, Sally Rockey dives into National Institutes of Health funding data.